ADVICE: in the absence of a submission from the holder of the marketing authorisation 
apalutamide (Erleada®) is not recommended for use within NHSScotland.

Indication under review: In adult men for the treatment of non-metastatic castration-resistant 
prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this 
product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:
No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful 
consideration and evaluation of the available evidence. It is provided to inform the considerations of 
Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for 
local use or local formulary inclusion. This advice does not override the individual responsibility of 
health professionals to make decisions in the exercise of their clinical judgement in the circumstances 
of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium